Comparative Pharmacology
Head-to-head clinical analysis: TEMARIL versus TRIPROLIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEMARIL versus TRIPROLIDINE HYDROCHLORIDE.
TEMARIL vs TRIPROLIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Temaril (trimeprazine tartrate and prednisolone) combines an antipruritic phenothiazine antihistamine with a corticosteroid. Trimeprazine blocks histamine H1 receptors, reducing pruritus and allergic reactions. Prednisolone suppresses inflammation via glucocorticoid receptor activation, inhibiting phospholipase A2 and cytokine production.
Competitive antagonist of histamine H1 receptors; inhibits histamine-mediated vasodilation, increased capillary permeability, and bronchoconstriction in allergic reactions.
2.5 mg orally twice daily or 5 mg orally at bedtime; maximum 10 mg/day.
2.5 mg orally every 4-6 hours as needed; maximum 10 mg per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in adults; prolonged in hepatic impairment (up to 20 hours). Given TID dosing, steady state is reached within 2 days.
Terminal elimination half-life approximately 3–4 hours in healthy adults; prolonged in renal impairment (up to 12 hours).
Primarily via kidneys as metabolites; unchanged drug accounts for <1%. Biliary/fecal excretion is minor. Approx. 90% recovered in urine within 24 hours.
Renal (primarily as metabolites; ~70% recovered in urine within 24 hours, <5% unchanged). Fecal elimination is minor.
Category C
Category A/B
Antihistamine
Antihistamine